BiotechTube

NBI-98854 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tourette Syndrome

Conditions

Tourette Syndrome

Trial Timeline

Nov 1, 2015 → Dec 1, 2016

NCT ID
NCT02581865

About NBI-98854 + Placebo

NBI-98854 + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Tourette Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02581865. Target conditions include Tourette Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02679079Phase 2Completed
NCT02581865Phase 2Completed
NCT02274558Phase 3Completed

Competing Products

12 competing products in Tourette Syndrome

See all competitors
ProductCompanyStageHype Score
AZD5213 and placeboAstraZenecaPhase 2
52
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
51
AripiprazoleBristol Myers SquibbPre-clinical
22
NBI-98854Neurocrine BiosciencesPhase 2
49
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
NBI-98854Neurocrine BiosciencesPhase 1
30
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
49
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
49
ValbenazineNeurocrine BiosciencesPhase 2
49
Abobotulinum toxin AIpsenPre-clinical
20
Tetrabenazine MR + PlaceboBausch HealthPhase 2
47

Other Products from Neurocrine Biosciences

Valbenazine Oral CapsuleApproved
82
ValbenazineApproved
82
ValbenazineApproved
82
Valbenazine + Placebo oral capsuleApproved
82
Valbenazine + Placebo oral capsuleApproved
82